Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Summary In 2019, Germany passed the Digital Healthcare Act, which, among other things,
created a" Fast-Track" regulatory and reimbursement pathway for digital health applications …

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light
of the multitude of recent phase III trials that have failed to meet their primary endpoints …

Highlights•Considerations for the use of external controls in oncology clinical trials are
multifaceted and depend on the intended use.•Review of recent research and some …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Integration of external control data, with patient-level information, in clinical trials has the
potential to accelerate the development of new treatments in neuro-oncology by …

We reviewed foundational concepts in artificial intelligence (AI) and machine learning (ML)
and discussed ways in which these methodologies may be employed to enhance progress …

Multi-omic data, ie, clinical measures, radiomic, and genetic data, capture multi-faceted
tumor characteristics, contributing to a comprehensive patient risk assessment. Here, we …

Natural language processing (NLP), which aims to convert human language into
expressions that can be analyzed by computers, is one of the most rapidly developing and …